Poolbeg Pharma files patent for POLB 001 to be used in cancer treatments

Poolbeg Pharma, a biopharmaceutical company that specialises in infectious diseases, has filed a patent for one of its treatments to be used in cancer treatments.

The treatment, called POLB 001, was developed to address severe influenza, but it has been found to have the potential to address life-threatening side effects in cancer treatment as well.

The London-based Irish company announced that while investigating the role of cytokine release syndrome (CRS) in severe influenza, it discovered data specific to the overt immune response in CAR T cell patients that suggest POLB 001 as a potential treatment.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. POLB 001 has the potential to dampen the pro-inflammatory cytokine release syndrome affecting patients receiving CAR T cell therapies

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma updates on Immunomodulator II Patent

Poolbeg Pharma has announced that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a precursor to the expected formal grant

February hires in Pharma

February may be the shortest month, but we got an extra day this year and that left plenty of time for personnel announcements in the pharma world. Read on for a roundup of the month’s hiring

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a